Eliksa Therapeutics

02/28/2025

Rare diseases are not rare, they impact over 300 million people worldwide. At Eliksa Therapeutics we are committed to advancing solutions for those who need it most. We are currently conducting the first clinical trial for treating ocular manifestations of Epidermolysis Bullosa. Learn more about EB and our work at www.eliksa.com/eb

Image adapted from rarediseaseday.org materials.

12/17/2024

As we wrap up the year, we are excited to share progress on our ongoing clinical trial addressing the ocular manifestations of Epidermolysis Bullosa. Currently, 5 participants are in the treatment phase, applying ELK-003 eye drops daily, with additional participants expected to begin soon. This milestone reflects the collaborative efforts of our team, Fundación DEBRA Chile-Niños Piel de Cristal, and the broader EB community.

We extend our sincere appreciation to the individuals, investors, and foundations supporting this important work:
Fundación DEBRA Chile-Niños Piel de Cristal
EB Research Partnership
Militia Hill Ventures
Ben Franklin Technology Partners
Pennsylvania Biotechnology Center
University of Utah

Looking ahead to 2025, we remain committed to advancing this study and eagerly anticipate results that could make a meaningful difference for the EB community.

08/06/2024

Our team had a fantastic time at Debra Care 2024! We learned a lot and were reminded why we're working so hard on a therapy for ocular EB.

Huge thanks to the debra of America organizers and team for putting together such a great event. We’re excited to keep moving forward!

02/29/2024

Today, on Rare Disease Day, we had the honor of visiting Fundación Debra Chile, marking a significant milestone in our ongoing collaboration, as we move closer to launching the first clinical trial for ocular manifestations of epidermolysis bullosa.

11/14/2023

Thank you to debra of America for honoring us with the Partners in Progress Award recognizing our efforts in developing ELK-003, a novel eye drop for treating the ocular manifestations of Epidermolysis Bullosa.

Special thanks to the incredible Eliksa Therapeutics team whose unwavering dedication and collaborative spirit made this achievement possible.

10/20/2023

We are honored to receive this award from debra of America for our groundbreaking work in developing a novel eye drop (ELK-003) to treat ocular manifestation of Epidermolysis Bullosa.

At Eliksa Therapeutics, our dedication to improving the lives of EB patients drives us forward, and ELK-003 represents a major step in our ongoing journey to make a meaningful impact in their ocular treatment and well-being.

Announcing our 2023 Partners in Progress Award Honoree: Eliksa Therapeutics! ✨🎉

Eliksa is developing the first-ever eye drop (ELK-003) to treat corneal abrasions in those with Epidermolysis Bullosa (EB). Join us on November 4, 2023 at Georgia Aquarium to honor our friends at Eliksa at the !

➡️ Learn more about Eliksa and their work at https://debra.pulse.ly/i10lxxbt38

02/28/2023

Did you know over 300 million people worldwide are living with a rare disease, but less than 5% of these diseases have a treatment approved by the FDA?

We are proud to be supporting the rare disease community by developing the first treatment for ocular Epidermolysis Bullosa!

12/21/2022

Wishing you a Happy Holiday and a joyful New Year. Best wishes from your friends at Eliksa Therapeutics ✨

12/14/2022

Research Update! 🔬 Eliksa Therapeutics is developing the first treatment for ocular manifestations of Epidermolysis Bullosa (EB).

➡️ Join the Patient Advisory Group to help guide the development of this new and exciting drug at eliksa.com/eb

11/19/2022

🔬 Research News! Eliksa Therapeutics is developing the first treatment for ocular manifestation of Recessive Dystrophic Epidermolysis Bullosa (RDEB).

➡️ Stay tuned by subscribing at eliksa.com/eb and following them on Facebook.